Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHRQ on heart disease treatments

This article was originally published in The Gray Sheet

Executive Summary

Long-term freedom from chest pain and repeat revascularization is significantly greater with coronary artery bypass surgery than angioplasty, but CABG causes significantly more post-procedure strokes, the Agency for Healthcare Research and Quality concludes in a comparative-effectiveness literature 1review finalized Oct. 15. Overall survival rates were similar. The AHRQ review included analysis of 23 randomized controlled trials comparing percutaneous coronary intervention to CABG. The report, released in draft form in January, says there is not enough data to assess comparative effectiveness in specific patient subgroups and that more study results are needed to assess the impact of stents, and drug-eluting stents in particular, on outcomes (2"The Gray Sheet" Jan. 29, 2007, p. 16)
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT025379

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel